Mindray Medical International Ltd (ADR) (MR): Are Hedge Funds Right About This Stock?

Page 1 of 2

Mindray Medical International Ltd (ADR) (NYSE:MR) shareholders have witnessed an increase in hedge fund sentiment of late.

At the moment, there are dozens of metrics investors can use to analyze stocks. A couple of the most innovative are hedge fund and insider trading sentiment. At Insider Monkey, our research analyses have shown that, historically, those who follow the top picks of the best money managers can outpace their index-focused peers by a significant amount (see just how much).

Equally as integral, bullish insider trading sentiment is another way to parse down the marketplace. Obviously, there are a number of stimuli for a corporate insider to cut shares of his or her company, but just one, very obvious reason why they would buy. Plenty of empirical studies have demonstrated the impressive potential of this strategy if piggybackers know where to look (learn more here).

Now, we’re going to take a look at the key action encompassing Mindray Medical International Ltd (ADR) (NYSE:MR).

How have hedgies been trading Mindray Medical International Ltd (ADR) (NYSE:MR)?

At the end of the first quarter, a total of 11 of the hedge funds we track were long in this stock, a change of 10% from the previous quarter. With hedgies’ positions undergoing their usual ebb and flow, there exists a few notable hedge fund managers who were increasing their holdings meaningfully.

Mindray Medical International Ltd (ADR) (NYSE:MR)Of the funds we track, William B. Gray’s Orbis Investment Management had the biggest position in Mindray Medical International Ltd (ADR) (NYSE:MR), worth close to $86.9 million, accounting for 0.7% of its total 13F portfolio. The second largest stake is held by David Blood and Al Gore of Generation Investment Management, with a $37.1 million position; 0.8% of its 13F portfolio is allocated to the stock. Some other peers with similar optimism include Kerr Neilson’s Platinum Asset Management, Jim Simons’s Renaissance Technologies and J. Alan Reid, Jr.’s Forward Management.

With a general bullishness amongst the heavyweights, key money managers were leading the bulls’ herd. Platinum Asset Management, managed by Kerr Neilson, assembled the most outsized position in Mindray Medical International Ltd (ADR) (NYSE:MR). Platinum Asset Management had 22.3 million invested in the company at the end of the quarter. D. E. Shaw’s D E Shaw also made a $1.1 million investment in the stock during the quarter. The other funds with brand new MR positions are Bruce Kovner’s Caxton Associates LP, Mike Vranos’s Ellington, and Samuel Isaly’s OrbiMed Advisors.

What have insiders been doing with Mindray Medical International Ltd (ADR) (NYSE:MR)?

Insider purchases made by high-level executives is at its handiest when the primary stock in question has seen transactions within the past half-year. Over the last half-year time frame, Mindray Medical International Ltd (ADR) (NYSE:MR) has seen zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).

Let’s go over hedge fund and insider activity in other stocks similar to Mindray Medical International Ltd (ADR) (NYSE:MR). These stocks are C.R. Bard, Inc. (NYSE:BCR), CareFusion Corporation (NYSE:CFN), Teleflex Incorporated (NYSE:TFX), DENTSPLY International Inc. (NASDAQ:XRAY), and The Cooper Companies, Inc. (NYSE:COO). This group of stocks are in the medical instruments & supplies industry and their market caps are similar to MR’s market cap.

Page 1 of 2